TY - JOUR
T1 - Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor
T2 - Implications for ocular angiogenesis
AU - Duh, Elia J.
AU - Yang, Hoseong S.
AU - Haller, Julia A.
AU - De Juan, Eugene
AU - Humayun, Mark S.
AU - Gehlbach, Peter
AU - Melia, Michele
AU - Pieramici, Dante
AU - Harlan, J. B.
AU - Campochiaro, Peter A.
AU - Zack, Donald J.
PY - 2004/4
Y1 - 2004/4
N2 - Purpose Pigment epithelium-derived factor (PEDF) has been demonstrated to suppress ocular angiogenesis in several animal models. In this study, we sought to measure the levels of PEDF and vascular endothelial growth factor (VEGF) in the vitreous of patients with and without ocular neovascular disorders. Design Case-control study of patients undergoing intraocular surgery for a variety of neovascular and nonneovascular conditions. Methods Vitreous samples were collected from 65 eyes of 65 patients with no neovascular disorder (n = 24), choroidal neovascularization (n = 9), active proliferative diabetic retinopathy (n = 16), and inactive proliferative diabetic retinopathy (n = 16). The levels of VEGF and PEDF in these vitreous samples were determined by enzyme-linked immunosorbent assay. Results The VEGF levels were at or below the level of detectability in the reference and choroidal neovascularization groups. The VEGF levels were significantly elevated in both the active and inactive PDR groups, and significantly higher in the active PDR group as compared with the inactive PDR group. The PEDF levels, which were present at relatively high concentrations in all groups, were higher in patients with active PDR compared with the control and choroidal neovascularization groups. Conclusions High levels of immunoreactive PEDF are present in the vitreous of individuals with or without ocular neovascularization, but PEDF levels are significantly higher in patients with active PDR compared with patients with choroidal neovascularization or nonneovascular retinal diseases. Although these results do not preclude the possibility that endogenous PEDF helps to modulate ocular neovascularization, they do not support ischemia-induced downregulation of PEDF as a mechanism for such modulation.
AB - Purpose Pigment epithelium-derived factor (PEDF) has been demonstrated to suppress ocular angiogenesis in several animal models. In this study, we sought to measure the levels of PEDF and vascular endothelial growth factor (VEGF) in the vitreous of patients with and without ocular neovascular disorders. Design Case-control study of patients undergoing intraocular surgery for a variety of neovascular and nonneovascular conditions. Methods Vitreous samples were collected from 65 eyes of 65 patients with no neovascular disorder (n = 24), choroidal neovascularization (n = 9), active proliferative diabetic retinopathy (n = 16), and inactive proliferative diabetic retinopathy (n = 16). The levels of VEGF and PEDF in these vitreous samples were determined by enzyme-linked immunosorbent assay. Results The VEGF levels were at or below the level of detectability in the reference and choroidal neovascularization groups. The VEGF levels were significantly elevated in both the active and inactive PDR groups, and significantly higher in the active PDR group as compared with the inactive PDR group. The PEDF levels, which were present at relatively high concentrations in all groups, were higher in patients with active PDR compared with the control and choroidal neovascularization groups. Conclusions High levels of immunoreactive PEDF are present in the vitreous of individuals with or without ocular neovascularization, but PEDF levels are significantly higher in patients with active PDR compared with patients with choroidal neovascularization or nonneovascular retinal diseases. Although these results do not preclude the possibility that endogenous PEDF helps to modulate ocular neovascularization, they do not support ischemia-induced downregulation of PEDF as a mechanism for such modulation.
UR - http://www.scopus.com/inward/record.url?scp=11144357806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144357806&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2003.11.015
DO - 10.1016/j.ajo.2003.11.015
M3 - Article
C2 - 15059706
AN - SCOPUS:11144357806
SN - 0002-9394
VL - 137
SP - 668
EP - 674
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 4
ER -